Molecular Partners AG
SIX:MOLN
Molecular Partners AG
Total Equity
Molecular Partners AG
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Total Equity
CHf95.5m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Equity
$1.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
49%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Equity
CHf127.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Equity
-CHf1.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Equity
CHf73.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Equity
CHf32.6m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Total Equity?
Total Equity
95.5m
CHF
Based on the financial report for Sep 30, 2025, Molecular Partners AG's Total Equity amounts to 95.5m CHF.
What is Molecular Partners AG's Total Equity growth rate?
Total Equity CAGR 3Y
-28%
Over the last year, the Total Equity growth was -31%. The average annual Total Equity growth rates for Molecular Partners AG have been -28% over the past three years .
